On peptides and altered peptide ligands: From origin, mode of action and design to clinical application (Immunotherapy)

International Archives of Allergy and Immunology

Volumn 170, Issue 4, 2016, Pages 211-233

  Candia, Martín ^a   Kratzer, Bernhard ^a   Pickl, Winfried F ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

Author keywords

Altered peptide ligand; Immunotherapy; Peptides; T cell activation; T cell epitopes; T cell responses; T cells

Indexed keywords

ALLERGEN; ALTERED PEPTIDE LIGAND; ANTIALLERGIC AGENT; BEE VENOM; COLLAGEN TYPE 4; CYTOCHROME C; GAG PROTEIN; GAG PROTEIN[33-41]; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN[18-27]; IMMUNOMODULATING AGENT; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ[307-319]; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LIGAND; MOTH CYTOCHROME C[88-103]; OVALBUMIN; OVALBUMIN[257-264]; PEPTIDE; PIGEON CYTOCHROME C[88-104]; POLLEN ANTIGEN; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR; TETANUS TOXOID; TETANUS TOXOID[830-843]; TOLL LIKE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; EPITOPE; HISTOCOMPATIBILITY ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ALLERGIC DISEASE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; REVIEW; T LYMPHOCYTE; WILD TYPE; ANIMAL; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PRECLINICAL STUDY; PROCEDURES; SIGNAL TRANSDUCTION;

ALLERGENS; ANIMALS; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EPITOPES; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; LIGANDS; LYMPHOCYTE ACTIVATION; PEPTIDES; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84988646234     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000448756     Document Type: Review

References (210)

1. Evavold BD, Allen PM: Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308-1310
2. Evavold BD, Williams SG, Hsu BL, Buus S, Allen PM: Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J Immunol 1992; 148: 347-353
3. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, Sette A: Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992; 68: 625-634
4. Jameson SC, Carbone FR, Bevan MJ: Clonespecific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J Exp Med 1993; 177: 1541-1550
5. Ostrov D, Krieger J, Sidney J, Sette A, Concannon P: T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. J Immunol 1993; 150: 4277-4283
6. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR: T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27
7. Wauben MH, Boog CJ, van der Zee R, Joosten I, Schlief A, van Eden W: Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J Exp Med 1992; 176: 667-677
8. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L: Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor α production. J Exp Med 1994; 180: 2227-2237
9. Evavold BD, Sloan-Lancaster J, Allen PM: Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 1993; 14: 602-609
10. Sloan-Lancaster J, Evavold BD, Allen PM: Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156-159
11. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K: Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181: 1569-1574
12. Racioppi L, Ronchese F, Matis LA, Germain RN: Peptide-major histocompatibility complex class II complexes with mixed agonist/ antagonist properties provide evidence for ligand-related differences in T cell receptordependent intracellular signaling. J Exp Med 1993; 177: 1047-1060
13. Page DM, Alexander J, Snoke K, Appella E, Sette A, Hedrick SM, Grey HM: Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists. Proc Natl Acad Sci USA 1994; 91: 4057-4061
14. Robertson JM, Evavold BD: Cutting edge: dueling TCRs: peptide antagonism of CD4+ T cells with dual antigen specificities. J Immunol 1999; 163: 1750-1754
15. Dittel BN, Stefanova I, Germain RN, Janeway CA Jr: Cross-antagonism of a T cell clone expressing two distinct T cell receptors. Immunity 1999; 11: 289-298
16. Yang W, Grey HM: Study of the mechanism of TCR antagonism using dual-TCR-expressing T cells. J Immunol 2003; 170: 4532-4538
17. Jones DS, Reichardt P, Ford ML, Edwards LJ, Evavold BD: TCR antagonism by peptide requires high TCR expression. J Immunol 2008; 181: 1760-1766
18. Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN: TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003; 4: 248-254
19. Wylie DC, Das J, Chakraborty AK: Sensitivity of T cells to antigen and antagonism emerges from differential regulation of the same molecular signaling module. Proc Natl Acad Sci USA 2007; 104: 5533-5538
20. Lafferty KJ, Cunningham AJ: A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53: 27-42
21. Sloan-Lancaster J, Allen PM: Significance of T-cell stimulation by altered peptide ligands in T cell biology. Curr Opin Immunol 1995; 7: 103-109
22. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM: Partial T cell signaling: altered phospho- and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994; 79: 913-922
23. Rabinowitz JD, Beeson C, Wulfing C, Tate K, Allen PM, Davis MM, McConnell HM: Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 1996; 5: 125-135
24. McConnell HM, Owicki JC, Parce JW, Miller DL, Baxter GT, Wada HG, Pitchford S: The cytosensor microphysiometer: biological applications of silicon technology. Science 1992; 257: 1906-1912
25. Boutin Y, Leitenberg D, Tao X, Bottomly K: Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naive CD4+ T cells into Th1 and Th2 subsets. J Immunol 1997; 159: 5802-5809
26. Kersh GJ, Kersh EN, Fremont DH, Allen PM: High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 1998; 9: 817-826
27. Sloan-Lancaster J, Allen PM: Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14: 1-27
28. Sloan-Lancaster J, Evavold BD, Allen PM: Th2 cell clonal anergy as a consequence of partial activation. J Exp Med 1994; 180: 1195-1205
29. Sloan-Lancaster J, Steinberg TH, Allen PM: Selective activation of the calcium signaling pathway by altered peptide ligands. J Exp Med 1996; 184: 1525-1530
30. Ding L, Shevach EM: Differential effects of CD28 engagement and IL-12 on T cell activation by altered peptide ligands. J Immunol 1998; 161: 6614-6621
31. van Bergen J, Koning F: Altered peptide ligands and wild-type peptide induce indistinguishable responses of a human Th0 clone. Eur J Immunol 1998; 28: 2801-2808
32. Faber-Elmann A, Grabovsky V, Dayan M, Sela M, Alon R, Mozes E: Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. Int Immunol 2000; 12: 1651-1658
33. Hollsberg P, Weber WE, Dangond F, Batra V, Sette A, Hafler DA: Differential activation of proliferation and cytotoxicity in human Tcell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. Proc Natl Acad Sci USA 1995; 92: 4036-4040
34. Tao X, Grant C, Constant S, Bottomly K: Induction of IL-4-producing CD4+ T cells by antigenic peptides altered for TCR binding. J Immunol 1997; 158: 4237-4244
35. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK: An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397-405
36. Kersh GJ, Allen PM: Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 1996; 184: 1259-1268
37. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM: Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol 1993; 150: 3131-3140
38. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J, Sidney J, Delguercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV: The relationship between class-I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J Immunol 1994; 153: 5586-5592
39. Lipford GB, Bauer S, Wagner H, Heeg K: In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine 1995; 13: 313-320
40. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J: Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994; 180: 1471-1483
41. Webb AI, Dunstone MA, Chen W, Aguilar MI, Chen Q, Jackson H, Chang L, Kjer- Nielsen L, Beddoe T, McCluskey J, Rossjohn J, Purcell AW: Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J Biol Chem 2004; 279: 23438-23446
42. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A∗0201- binding residues. J Immunol 1996; 157: 2539-2548
43. Borbulevych OY, Baxter TK, Yu ZY, Restifo NP, Baker BM: Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/ MHC complex: implications for vaccine design. J Immunol 2005; 174: 4812-4820
44. Denkberg G, Klechevsky E, Reiter Y: Modification of a tumor-derived peptide at an HLAA2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J Immunol 2002; 169: 4399-4407
45. Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V: Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165: 948-955
46. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, Achour A: Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res 2009; 69: 7784-7792
47. Chen S, Li Y, Depontieu FR, McMiller TL, English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA, Hunt DF, Mariuzza RA, Topalian SL: Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. J Immunol 2013; 191: 5097-5106
48. Jameson SC, Hogquist KA, Bevan MJ: Specificity and flexibility in thymic selection. Nature 1994; 369: 750-752
49. Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher HP, Zinkernagel RM, Tonegawa S: Evidence for a differential avidity model of T cell selection in the thymus. Cell 1994; 76: 651-663
50. Hsu BL, Evavold BD, Allen PM: Modulation of T cell development by an endogenous altered peptide ligand. J Exp Med 1995; 181: 805-810
51. Berkley AM, Fink PJ: Cutting edge: CD8+ recent thymic emigrants exhibit increased responses to low-affinity ligands and improved access to peripheral sites of inflammation. J Immunol 2014; 193: 3262-3266
52. Barbera A, Lorenzo N, Garrido G, Mazola Y, Falcon V, Torres AM, Hernandez MI, Hernandez MV, Margry B, de Groot AM, van Roon J, van der Zee R, Broere F, van Eden W, Padron G, Dominguez Mdel C: APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients. Int Immunopharmacol 2013; 17: 1075-1083
53. Lorenzo N, Cantera D, Barbera A, Alonso A, Chall E, Franco L, Ancizar J, Nunez Y, Altruda F, Silengo L, Padron G, Del Carmen Dominguez M: APL-2, an altered peptide ligand derived from heat-shock protein 60, induces interleukin-10 in peripheral blood mononuclear cell derived from juvenile idiopathic arthritis patients and downregulates the inflammatory response in collagen-induced arthritis model. Clin Exp Med 2015; 15: 31-39
54. Faber-Elmann A, Grabovsky V, Dayan M, Sela M, Alon R, Mozes E: An altered peptide ligand inhibits the activities of matrix metalloproteinase-and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope. FASEB J 2001; 15: 187-194
55. Paas-Rozner M, Sela M, Mozes E: The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci USA 2001; 98: 12642-12647
56. Paas-Rozner M, Sela M, Mozes E: A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells. Proc Natl Acad Sci USA 2003; 100: 6676-6681
57. Ben-David H, Sharabi A, Dayan M, Sela M, Mozes E: The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc Natl Acad Sci USA 2007; 104: 17459-17464
58. Ben-David H, Aruna BV, Seger R, Sela M, Mozes E: A 50-kDa ERK-like protein is upregulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc Natl Acad Sci USA 2006; 103: 18232-18237
59. Ben-David H, Sela M, Mozes E: Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+- regulated events leading to apoptosis. Proc Natl Acad Sci USA 2005; 102: 2028-2033
60. Norris PJ, Stone JD, Anikeeva N, Heitman JW, Wilson IC, Hirschkorn DF, Clark MJ, Moffett HF, Cameron TO, Sykulev Y, Stern LJ, Walker BD: Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope. Mol Immunol 2006; 43: 1349-1357
61. Purbhoo MA, Sewell AK, Klenerman P, Goulder PJ, Hilyard KL, Bell JI, Jakobsen BK, Phillips RE: Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. Proc Natl Acad Sci USA 1998; 95: 4527-4532
62. Burroughs NJ, Rand DA: Dynamics of T-cell antagonism: enhanced viral diversity and survival. Proc Biol Sci 1998; 265: 529-535
63. Frasca L, Del Porto P, Tuosto L, Marinari B, Scotta C, Carbonari M, Nicosia A, Piccolella E: Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J Immunol 1999; 163: 650-658
64. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F, Ferrari C: Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407-410
65. Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, Aidoo M, Kwiatkowski D, Greenwood BM, Whittle HC, Hill AV: Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998; 279: 1173-1177
66. McAdam SN, Fleckenstein B, Rasmussen IB, Schmid DG, Sandlie I, Bogen B, Viner NJ, Sollid LM: T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation. J Exp Med 2001; 193: 1239-1246
67. Mamula MJ, Gee RJ, Elliott JI, Sette A, Southwood S, Jones PJ, Blier PR: Isoaspartyl posttranslational modification triggers autoimmune responses to self-proteins. J Biol Chem 1999; 274: 22321-22327
68. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E: Cutting edge: the conversion of arginine to citrulline allows for a highaffinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1∗0401 MHC class II molecule. J Immunol 2003; 171: 538-541
69. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L, Catrina AI: Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006; 65: 1219-1222
70. Kim JK, Mastronardi FG, Wood DD, Lubman DM, Zand R, Moscarello MA: Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics 2003; 2: 453-462
71. Ireland J, Herzog J, Unanue ER: Cutting edge: Unique T cells that recognize citrullinated peptides are a feature of protein immunization. J Immunol 2006; 177: 1421-1425
72. Nakashima K, Hagiwara T, Ishigami A, Nagata S, Asaga H, Kuramoto M, Senshu T, Yamada M: Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1α,25-dihydroxyvitamin D 3 . J Biol Chem 1999; 274: 27786-27792
73. Ireland JM, Unanue ER: Autophagy in antigen- presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med 2011; 208: 2625-2632
74. Tighe MR, Hall MA, Barbado M, Cardi E, Welsh KI, Ciclitira PJ: HLA class II alleles associated with celiac disease susceptibility in a southern European population. Tissue Antigens 1992; 40: 90-97
75. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E: Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J Exp Med 1989; 169: 345-350
76. Schuppan D, Junker Y, Barisani D: Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912-1933
77. Lundin KE, Scott H, Fausa O, Thorsby E, Sollid LM: T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum Immunol 1994; 41: 285-291
78. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801
79. Elli L, Bergamini CM, Bardella MT, Schuppan D: Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009; 41: 541-550
80. Greenberg CS, Birckbichler PJ, Rice RH: Transglutaminases: multifunctional crosslinking enzymes that stabilize tissues. FASEB J 1991; 5: 3071-3077
81. Bruce SE, Bjarnason I, Peters TJ: Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin Sci (Lond) 1985; 68: 573-579
82. Molberg O, Kett K, Scott H, Thorsby E, Sollid LM, Lundin KE: Gliadin specific, HLA DQ2- restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand J Immunol 1997; 46: 103-109
83. Lundin KE, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O, Thorsby E, Sollid LM: Gliadin-specific, HLA-DQ(α1∗0501,β1∗0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993; 178: 187-196
84. van de Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Papadopoulos G, Koning F: Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998; 161: 1585-1588
85. Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, Madsen L, Fugger L, Scott H, Noren O, Roepstorff P, Lundin KE, Sjostrom H, Sollid LM: Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713-717
86. Arentz-Hansen H, McAdam SN, Molberg O, Fleckenstein B, Lundin KE, Jorgensen TJ, Jung G, Roepstorff P, Sollid LM: Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002; 123: 803-809
87. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C: Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275-2279
88. Vader W, Kooy Y, Van Veelen P, De Ru A, Harris D, Benckhuijsen W, Pena S, Mearin L, Drijfhout JW, Koning F: The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002; 122: 1729-1737
89. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM: Structural basis for HLA-DQ2- mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004; 101: 4175-4179
90. Henderson KN, Tye-Din JA, Reid HH, Chen Z, Borg NA, Beissbarth T, Tatham A, Mannering SI, Purcell AW, Dudek NL, van Heel DA, McCluskey J, Rossjohn J, Anderson RP: A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 2007; 27: 23-34
91. Fleckenstein B, Molberg O, Qiao SW, Schmid DG, von der Mulbe F, Elgstoen K, Jung G, Sollid LM: Gliadin T cell epitope selection by tissue transglutaminase in celiac disease: role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem 2002; 277: 34109-34116
92. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV: In vivo antigen challenge in celiac disease identifies a single transglutaminase- modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6: 337-342
93. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Vader W, Kooy YM, Lundin KE, Koning F, Roepstorff P, Sollid LM, McAdam SN: The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000; 191: 603-612
94. Qiao SW, Bergseng E, Molberg O, Xia J, Fleckenstein B, Khosla C, Sollid LM: Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 2004; 173: 1757-1762
95. Xia J, Sollid LM, Khosla C: Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2. Biochemistry 2005; 44: 4442-4449
96. Xia J, Siegel M, Bergseng E, Sollid LM, Khosla C: Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from α2-gliadin. J Am Chem Soc 2006; 128: 1859-1867
97. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH: Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000; 192: 1755-1762
98. Birnboim HC, Lemay AM, Lam DK, Goldstein R, Webb JR: Cutting edge: MHC class II-restricted peptides containing the inflammation- associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cellmediated immune response. J Immunol 2003; 171: 528-532
99. Stockl J, Majdic O, Fischer G, Maurer D, Knapp W: Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-A1-restricted, hapten-specific CTL. J Immunol 2001; 167: 2724-2733
100. Herzog J, Maekawa Y, Cirrito TP, Illian BS, Unanue ER: Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells. Proc Natl Acad Sci USA 2005; 102: 7928-7933
101. Martin SF: T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int Arch Allergy Immunol 2004; 134: 186-198
102. Martin SF, Esser PR, Weber FC, Jakob T, Freudenberg MA, Schmidt M, Goebeler M: Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011; 66: 1152-1163
103. Pichler WJ, Adam J, Watkins S, Wuillemin N, Yun J, Yerly D: Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immunol 2015; 168: 13-24
104. Preckel T, Hellwig S, Pflugfelder U, Lappin MB, Weltzien HU: Clonal anergy induced in a CD8+ hapten-specific cytotoxic T-cell clone by an altered hapten-peptide ligand. Immunology 2001; 102: 8-14
105. Preckel T, Breloer M, Kohler H, von Bonin A, Weltzien HU: Partial agonism and independent modulation of T cell receptor and CD8 in hapten-specific cytotoxic T cells. Eur J Immunol 1998; 28: 3706-3718
106. Viner NJ, Nelson CA, Deck B, Unanue ER: Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol 1996; 156: 2365-2368
107. Viner NJ, Nelson CA, Unanue ER: Identification of a major I-Ek-restricted determinant of hen egg lysozyme: limitations of lymph node proliferation studies in defining immunodominance and crypticity. Proc Natl Acad Sci USA 1995; 92: 2214-2218
108. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER: Cutting edge: a single MHC anchor residue alters the conformation of a peptide-MHC complex inducing T cells that survive negative selection. J Immunol 2001; 166: 5874-5877
109. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER: Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 1999; 11: 453-462
110. Suri A, Lovitch SB, Unanue ER: The wide diversity and complexity of peptides bound to class II MHC molecules. Curr Opin Immunol 2006; 18: 70-77
111. Germain RN, Hendrix LR: MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 1991; 353: 134-139
112. Neefjes JJ, Ploegh HL: Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. EMBO J 1992; 11: 411-416
113. Lindner R, Unanue ER: Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J 1996; 15: 6910-6920
114. Cirrito TP, Pu Z, Deck MB, Unanue ER: Deamidation of asparagine in a major histocompatibility complex-bound peptide affects T cell recognition but does not explain type B reactivity. J Exp Med 2001; 194: 1165-1170
115. Sanderson F, Kleijmeer MJ, Kelly A, Verwoerd D, Tulp A, Neefjes JJ, Geuze HJ, Trowsdale J: Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 1994; 266: 1566-1569
116. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ: Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 1991; 349: 669-676
117. Harding CV: Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules. Semin Immunol 1995; 7: 355-360
118. Falk K, Lau JM, Santambrogio L, Esteban VM, Puentes F, Rotzschke O, Strominger JL: Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules. J Biol Chem 2002; 277: 2709-2715
119. Gupta S, Hopner S, Rupp B, Gunther S, Dickhaut K, Agarwal N, Cardoso MC, Kuhne R, Wiesmuller KH, Jung G, Falk K, Rotzschke O: Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules. PLoS One 2008; 3:e1814
120. Afridi S, Shaheen F, Roetzschke O, Shah ZA, Abbas SC, Siraj R, Makhmoor T: A cyclic peptide accelerates the loading of peptide antigens in major histocompatibility complex class II molecules. Biochem Biophys Res Commun 2015; 456: 774-779
121. Hopner S, Dickhaut K, Hofstatter M, Kramer H, Ruckerl D, Soderhall JA, Gupta S, Marin-Esteban V, Kuhne R, Freund C, Jung G, Falk K, Rotzschke O: Small organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket. J Biol Chem 2006; 281: 38535-38542
122. Call MJ, Xing X, Cuny GD, Seth NP, Altmann DM, Fugger L, Krogsgaard M, Stein RL, Wucherpfennig KW: In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol 2009; 182: 6342-6352
123. Govorkova EA, Fang HB, Tan M, Webster RG: Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004; 48: 4855-4863
124. Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, Pinto LH, Lamb RA: Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci USA 2008; 105: 10967-10972
125. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG: Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 5025-5037
126. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE: 1-[[(3-hydroxy- 1-adamantyl)amino]acetyl]-2-cyano-(S)- pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789
127. Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, Dahlberg HN, Schlossman SF, Morimoto C: Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992; 149: 481-486
128. Sakurada C, Sakurada S, Hayashi T, Katsuyama S, Tan-No K, Sakurada T: Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem Pharmacol 2003; 66: 653-661
129. Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, Letvin NL, Schlossman SF: 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989; 143: 3430-3439
130. Dickhaut K, Hoepner S, Eckhard J, Wiesmueller KH, Schindler L, Jung G, Falk K, Roetzschke O: Enhancement of tumourspecific immune responses in vivo by MHC loading-enhancer(MLE). PLoS One 2009; 4:e6811
131. Roy K, Naskar K, Ghosh M, Roy S: Class II MHC/peptide interaction in Leishmania donovani infection: implications in vaccine design. J Immunol 2014; 192: 5873-5880
132. Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, Bohle B: Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116: 213-219
133. Wangorsch A, Larsson H, Messmer M, Garcia- Moral A, Lauer I, Wolfheimer S, Schulke S, Bartra J, Vieths S, Lidholm J, Scheurer S: Molecular cloning of plane pollen allergen Pla a 3 and its utility as diagnostic marker for peach associated plane pollen allergy. Clin Exp Allergy 2016; 46: 764-774
134. Archila LD, Chow IT, McGinty JW, Renand A, Jeong D, Robinson D, Farrington ML, Kwok WW: Ana o 1 and Ana o 2 cashew allergens share cross-reactive CD4 + T-cell epitopes with other tree nuts. Clin Exp Allergy 2016; 46: 871-883
135. Kazatsky AM, Wood RA: Classification of food allergens and cross-reactivity. Curr Allergy Asthma Rep 2016; 16: 22
136. Kobayashi Y, Akiyama H, Huge J, Kubota H, Chikazawa S, Satoh T, Miyake T, Uhara H, Okuyama R, Nakagawara R, Aihara M, Hamada-Sato N: Fish collagen is an important panallergen in the Japanese population. Allergy 2016; 71: 720-723
137. Lukschal A, Wallmann J, Bublin M, Hofstetter G, Mothes-Luksch N, Breiteneder H, Pali-Scholl I, Jensen-Jarolim E: Mimotopes for Api g 5, a relevant cross-reactive allergen, in the celery-mugwort-birch-spice syndrome. Allergy Asthma Immunol Res 2016; 8: 124-131
138. Miyaji K, Okamoto N, Saito A, Yasueda H, Takase Y, Shimakura H, Saito S, Sakaguchi M: Cross-reactivity between major IgE core epitopes on Cry j 2 allergen of Japanese cedar pollen and relevant sequences on Cha o 2 allergen of Japanese cypress pollen. Allergol Int 2016; 65: 286-292
139. Westernberg L, Schulten V, Greenbaum JA, Natali S, Tripple V, McKinney DM, Frazier A, Hofer H, Wallner M, Sallusto F, Sette A, Peters B: T-cell epitope conservation across allergen species is a major determinant of immunogenicity. J Allergy Clin Immunol 2016; 138: 571-578.e7
140. Wuthrich B: Birch pollen allergy in relation with hypersensitivity for various kinds of fruit. Hautarzt 1990; 41: 583-584
141. Wuthrich B, Stager J, Johansson SG: Celery allergy associated with birch and mugwort pollinosis. Allergy 1990; 45: 566-571
142. Kleine-Tebbe J, Vogel L, Crowell DN, Haustein UF, Vieths S: Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22. J Allergy Clin Immunol 2002; 110: 797-804
143. Ebner C, Hirschwehr R, Bauer L, Breiteneder H, Valenta R, Ebner H, Kraft D, Scheiner O: Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995; 95: 962-969
144. Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, Breiteneder H, Kraft D, Ebner C: Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol 1998; 102: 679-686
145. Bohle B, Radakovics A, Jahn-Schmid B, Hoffmann-Sommergruber K, Fischer GF, Ebner C: Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level. Eur J Immunol 2003; 33: 3303-3310
146. Bohle B, Radakovics A, Luttkopf D, Jahn- Schmid B, Vieths S, Ebner C: Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens. Clin Exp Allergy 2005; 35: 1392-1399
147. Schimek EM, Zwolfer B, Briza P, Jahn- Schmid B, Vogel L, Vieths S, Ebner C, Bohle B: Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator- releasing, but not T cell-activating, capacity. J Allergy Clin Immunol 2005; 116: 1327-1333
148. Ikagawa S, Matsushita S, Chen YZ, Ishikawa T, Nishimura Y: Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J Allergy Clin Immunol 1996; 97: 53-64
149. Fasler S, Aversa G, de Vries JE, Yssel H: Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression, and help for IgE synthesis by Der p 1-specific human T-cell clones. J Allergy Clin Immunol 1998; 101: 521-530
150. Weghofer M, Dall'Antonia Y, Grote M, Stocklinger A, Kneidinger M, Balic N, Krauth MT, Fernandez-Caldas E, Thomas WR, van Hage M, Vieths S, Spitzauer S, Horak F, Svergun DI, Konarev PV, Valent P, Thalhamer J, Keller W, Valenta R, Vrtala S: Characterization of Der p 21, a new important allergen derived from the gut of house dust mites. Allergy 2008; 63: 758-767
151. Weghofer M, Grote M, Resch Y, Casset A, Kneidinger M, Kopec J, Thomas WR, Fernandez- Caldas E, Kabesch M, Ferrara R, Mari A, Purohit A, Pauli G, Horak F, Keller W, Valent P, Valenta R, Vrtala S: Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol 2013; 190: 3059-3067
152. Weghofer M, Thomas WR, Kronqvist M, Mari A, Purohit A, Pauli G, Horak F, Gronlund H, van Hage M, Valenta R, Vrtala S: Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008; 38: 959-965
153. De Palma R, Wu S, Sallusto F, Di Felice G, Martucci P, Geraci D, Colombo P, Troise C, Sacerdoti G, Nocera A, Gorski J: Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen. J Immunol 1999; 162: 1982-1987
154. Faith A, Akdis CA, Akdis M, Joss A, Wymann D, Blaser K: An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J Immunol 1999; 162: 1836-1842
155. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K: Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106
156. DeSilva DR, Urdahl KB, Jenkins MK: Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991; 147: 3261-3267
157. Kinnunen T, Kwok WW, Narvanen A, Rytkonen- Nissinen M, Immonen A, Saarelainen S, Taivainen A, Virtanen T: Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells. Int Immunol 2005; 17: 1573-1581
158. Kinnunen T, Buhot C, Narvanen A, Rytkonen- Nissinen M, Saarelainen S, Pouvelle- Moratille S, Rautiainen J, Taivainen A, Maillere B, Mantyjarvi R, Virtanen T: The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Eur J Immunol 2003; 33: 1717-1726
159. Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP, Wauben MH: Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol 2000; 164: 580-588
160. Moldaver D, Larche M: Immunotherapy with peptides. Allergy 2011; 66: 784-791
161. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern LJ, Gronlund H, van Hage M, Reynolds CJ, Boyton RJ, Cobbold SP, Kay AB, Altmann DM, Lloyd CM, Larche M: Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206: 1535-1547
162. Moldaver DM, Bharhani MS, Wattie JN, Ellis R, Neighbour H, Lloyd CM, Inman MD, Larche M: Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. Mucosal Immunol 2014; 7: 379-390
163. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90: 7608-7612
164. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ: T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139-1143
165. Critchfield JM, Zuniga-Pflucker JC, Lenardo MJ: Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell Immunol 1995; 160: 71-78
166. Gardner LM, O'Hehir RE, Rolland JM: High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-γ+ T cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol 2004; 133: 1-13
167. Liblau RS, Tisch R, Shokat K, Yang X, Dumont N, Goodnow CC, McDevitt HO: Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc Natl Acad Sci USA 1996; 93: 3031-3036
168. Suzuki G, Kawase Y, Koyasu S, Yahara I, Kobayashi Y, Schwartz RH: Antigen-induced suppression of the proliferative response of T cell clones. J Immunol 1988; 140: 1359-1365
169. Larche M, Wraith DC: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11:S69-S76
170. Bauer L, Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, Kraft D, Ebner C: Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997; 107: 536-541
171. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR: Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993; 178: 1783-1788
172. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC, O'Garra A: IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004; 172: 5986-5993
173. Anderson PO, Manzo BA, Sundstedt A, Minaee S, Symonds A, Khalid S, Rodriguez- Cabezas ME, Nicolson K, Li S, Wraith DC, Wang P: Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance. Eur J Immunol 2006; 36: 1374-1385
174. Pellaton C, Perrin Y, Boudousquie C, Barbier N, Wassenberg J, Corradin G, Thierry AC, Audran R, Reymond C, Spertini F: Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013; 3: 17
175. Couroux P, Patel D, Armstrong K, Larche M, Hafner RP: Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015; 45: 974-981
176. Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larche M, Hafner RP: Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo- controlled study. J Allergy Clin Immunol 2013; 131: 103-109.e7
177. Verhoef A, Alexander C, Kay AB, Larche M: T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2:e78
178. Leggatt GR: Peptide dose and/or structure in vaccines as a determinant of T cell responses. Vaccines (Basel) 2014; 2: 537-548
179. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF: Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154: 1623-1628
180. Badawi AH, Siahaan TJ: Immune modulating peptides for the treatment and suppression of multiple sclerosis. Clin Immunol 2012; 144: 127-138
181. Streeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC: Preclinical development and first-in-human study of ATXMS- 1467 for immunotherapy of MS. Neurol Neuroimmunol Neuroinflamm 2015; 2:e93
182. Hamburg MA, Collins FS: The path to personalized medicine. N Engl J Med 2010; 363: 301-304
183. Gran JT, Husby G, Thorsby E: The association between rheumatoid arthritis and the HLA antigen DR4. Ann Rheum Dis 1983; 42: 292-296
184. Gran JT, Husby G, Thorsby E: HLA DR antigens in rheumatoid arthritis. Scand J Rheumatol 1983; 12: 241-245
185. t Hart BA, Elferink DG, Drijfhout JW, Storm G, van Blooijs L, Bontrop RE, de Vries RR: Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Lett, 1997, 409:91-95.
186. Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H: Harnessing human dendritic cell subsets to design novel vaccines. Ann NY Acad Sci 2009; 1174: 24-32
187. Anderton SM, Manickasingham SP, Burkhart C, Luckcuck TA, Holland SJ, Lamont AG, Wraith DC: Fine specificity of the myelin- reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J Immunol 1998; 161: 3357-3364
188. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-1175
189. Anderton SM: Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 2001; 104: 367-376
190. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L: Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6: 1176-1182
191. Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O'Garra A: Interleukin-production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009; 31: 209-219
192. Rogers PR, Huston G, Swain SL: High antigen density and IL-2 are required for generation of CD4 effectors secreting Th1 rather than Th0 cytokines. J Immunol 1998; 161: 3844-3852
193. Pfeiffer C, Murray J, Madri J, Bottomly K: Selective activation of Th1- and Th2-like cells in vivo - response to human collagen IV. Immunol Rev 1991; 123: 65-84
194. Tian DH, Perera CJ, Apostolopoulos V, Moalem-Taylor G: Effects of vaccination with altered peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Front Neurol 2013; 4: 168
195. Perera CJ, Duffy SS, Lees JG, Kim CF, Cameron B, Apostolopoulos V, Moalem-Taylor G: Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury. J Neuroinflamm 2015; 12: 28
196. Cortes LM, Avichezer D, Silver PB, Luger D, Mattapallil MJ, Chan CC, Caspi RR: Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells. J Leukoc Biol 2008; 84: 577-585
197. Lau LL, Jamieson BD, Somasundaram T, Ahmed R: Cytotoxic T-cell memory without antigen. Nature 1994; 369: 648-652
198. Norman PS, Nicodemus CF, Creticos PS, et al: Clinical and immunologic effects of component peptides in Allervax cat. Int Arch Allergy Immunol 1997; 113: 1-3
199. Haselden BM, Kay AB, Larche M: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189: 1885-1894
200. Oldfield WL, Kay AB, Larche M: Allergenderived T cell peptide-induced late asthmatic reactions precede the induction of antigen- specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167: 1734-1739
201. Oldfield WL, Larche M, Kay AB: Effect of Tcell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360: 47-53
202. Alexander C, Ying S, A BK, Larche M: Fel d 1-derived T cell peptide therapy induces recruitment of CD4 + CD25 + ; CD4+ interferon- γ + T helper type 1 cells to sites of allergen- induced late-phase skin reactions in catallergic subjects. Clin Exp Allergy 2005; 35: 52-58
203. Alexander C, Tarzi M, Larche M, Kay AB: The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60: 1269-1274
204. Creticos PS, Hebert J, Philip G; The Allervax Ragweed Study Group: Efficacy of Allervax ragweed in the treatment of ragweed-induced allergy. J Allergy Clin Immunol 1997; 99:S401
205. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101: 747-754
206. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, Corradin G, Spertini F: Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111: 854-861
207. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larche M: Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36: 465-474
208. Texier C, Pouvelle S, Busson M, Herve M, Charron D, Menez A, Maillere B: HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000; 164: 3177-3184
209. Crowe PD, Qin Y, Conlon PJ, Antel JP: NBI- 5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000; 48: 758-765
210. Kinnunen T, Jutila K, Kwok WW, Rytkonen- Nissinen M, Immonen A, Saarelainen S, Narvanen A, Taivainen A, Virtanen T: Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J Allergy Clin Immunol 2007; 119: 965-972